Annual report pursuant to Section 13 and 15(d)

Non-Controlling Interests (Schedule of Non-Controlling Interests in Consolidated Entities) (Details)

v3.23.1
Non-Controlling Interests (Schedule of Non-Controlling Interests in Consolidated Entities) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Noncontrolling Interest [Line Items]    
NCI equity share $ 135,642 $ 217,326
Net loss attributable to non-controlling interests (127,338) (100,123)
Non-controlling interests in consolidated entities 8,304 117,203
Urica    
Noncontrolling Interest [Line Items]    
NCI equity share (2,657) (442)
Net loss attributable to non-controlling interests (1,251) (1,353)
Non-controlling interests in consolidated entities $ (3,908) $ (1,795)
Non-controlling ownership 40.20% 34.50%
Aevitas [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ (5,328) $ (4,159)
Net loss attributable to non-controlling interests (425) (901)
Non-controlling interests in consolidated entities $ (5,753) $ (5,060)
Non-controlling ownership 45.20% 45.90%
Avenue Therapeutics, Inc [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ 5,409 $ 5,739
Net loss attributable to non-controlling interests (2,355) (2,909)
Non-controlling interests in consolidated entities $ 3,054 $ 2,830
Non-controlling ownership 89.90% 82.00%
Baergic [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ 113 $ (2,047)
Net loss attributable to non-controlling interests (113) (39)
Non-controlling interests in consolidated entities   $ (2,086)
Non-controlling ownership   39.00%
Cellvation [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share (1,689) $ (1,413)
Net loss attributable to non-controlling interests (102) (131)
Non-controlling interests in consolidated entities $ (1,791) $ (1,544)
Non-controlling ownership 21.30% 21.70%
Checkpoint [Member].    
Noncontrolling Interest [Line Items]    
NCI equity share $ 32,398 $ 63,464
Net loss attributable to non-controlling interests (48,406) (39,226)
Non-controlling interests in consolidated entities $ (16,008) $ 24,238
Non-controlling ownership 82.20% 81.50%
Coronado SO [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ (291) $ (290)
Net loss attributable to non-controlling interests 0 0
Non-controlling interests in consolidated entities $ (291) $ (290)
Non-controlling ownership 13.00% 13.00%
Cyprium [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ (2,644) $ (1,397)
Net loss attributable to non-controlling interests (1,173) (807)
Non-controlling interests in consolidated entities $ (3,817) $ (2,204)
Non-controlling ownership 29.00% 29.80%
Helocyte [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ (5,778) $ (5,440)
Net loss attributable to non-controlling interests (122) (89)
Non-controlling interests in consolidated entities $ (5,900) $ (5,529)
Non-controlling ownership 17.90% 18.30%
JMC [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ 19,887 $ 23,150
Net loss attributable to non-controlling interests (12,458) (5,652)
Non-controlling interests in consolidated entities $ 7,429 $ 17,498
Non-controlling ownership 43.70% 41.60%
Mustang    
Noncontrolling Interest [Line Items]    
NCI equity share $ 98,461 $ 141,527
Net loss attributable to non-controlling interests (60,821) (48,518)
Non-controlling interests in consolidated entities $ 37,640 $ 93,009
Non-controlling ownership 81.30% 82.70%
Oncogenuity [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ (1,464) $ (627)
Net loss attributable to non-controlling interests (111) (497)
Non-controlling interests in consolidated entities $ (1,575) $ (1,124)
Non-controlling ownership 27.40% 24.90%
Tamid [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ (775) $ (739)
Net loss attributable to non-controlling interests (1) (1)
Non-controlling interests in consolidated entities $ (776) $ (740)
Non-controlling ownership 22.80% 22.80%